This pages provides you the latest drivers to solve your drivers dated, missing and conflicts problems and enhance your PC running more perfect. Here download WDM_R28.zip now. You can also use the Driver Doctor software to help you download and update your WDM_R28.zip driver, check out the files error information, then use this software to fix all problem directly. If you have any questions about this driver or another drivers, you can feel free to let me know by Contact Driver Doctor Support. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. Below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). Item 2.02. Results of Operations and Financial Condition. On August 3, 2016, Vitae Pharmaceuticals, Inc. (the Company or Vitae) issued a press release and is holding a conference call and webcast regarding its results of operations and financial condition for the quarter ended June 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the conference call are forward-looking statements under the securities laws, including, but not limited to, statements regarding Vitaes plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as, but not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The information included in this Current Report on Form 8-K pursuant to Item 7.01, including Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. ![]() (d) Exhibits Exhibit No. 99.1 Vitae Pharmaceuticals, Inc., Press Release, dated August 3, 2016 99.2 Presentation Slides Accompanying August 3, 2016 Vitae Pharmaceuticals Inc. Exhibit 99.1 Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, PA, August 3, 2016 Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended June 30, 2016. Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, During the quarter, we made significant progress towards the completion of two key milestones for Vitae. Download locations for Realtek High Definition Audio Driver for 2000/XP/2003 32/64-bit R2.74, Downloads: 2028456, Size: 30.50 MB. High definition audio driver from Realtek. WDM version 1.40 All the features that Windows XP supports, with the following exceptions. Hardware peak meters are supported, except when the Windows Vista mixer API runs in per-application mode. Movie Name: Bunny – (2005) Cast & Crew: Allu Arjun, Gowri Munjal Music: Devi Sri Prasad Category: Telugu Movies. Bunny songs free download| Bunny old. Sarrainodu (2016) Telugu mp3 songs download, Rakul Preet Singh, Catherine Tresa, Allu Arjun. Category: Telugu Movies. Telugu movie allu arjun / Bunny Telugu mp3; Sarinodu movie audio songs download, sarrainodu; Private Party. Doregama telugu old songs a to z; Ilayaraja telugu songs download; telugu old songs download; ilayaraja hits telugu; telugu old mp3 songs; telugu old hit songs. Bunny telugu movie songs free download doregama movies. Bunny Songs Download - Listen to telugu songs from Bunny MP3 songs online free. Play Bunny songs MP3. Download Bunny songs from Raaga.com. First, we are on track to report top-line results for the ongoing Phase 2a proof-of-concept study for VTP-38543, our wholly owned, potential first-in-class LXRβ selective agonist being developed for atopic dermatitis, in the fourth quarter of 2016. Second, we continue to finalize plans for the next clinical trial, expected to initiate in the fourth quarter of 2016, of VTP-43742, our wholly owned, first-in-class RORγt inhibitor, in psoriasis patients. Previously, VTP-43742 demonstrated results that validated RORγt as a therapeutic target for psoriasis and VTP-43742 as a potentially paradigm-changing therapeutic. Quarterly and Recent Highlights Pipeline Updates: VTP-38543 in Atopic Dermatitis Continued enrollment in its Phase 2a proof-of-concept clinical trial of VTP-38543 in atopic dermatitis. This four-week, randomized, double-blind, placebo-controlled Phase 2a trial will assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple ascending topical doses of VTP-38543 in approximately 100 adult patients with mild to moderate atopic dermatitis. Vitae expects to report top-line efficacy results in the fourth quarter of 2016. VTP-43742 in Autoimmune Disorders Continued preparations for an upcoming Phase 2 clinical trial of VTP-43742 in psoriasis patients. Vitae plans to advance VTP-43742 into a 16-week Phase 2 trial in the fourth quarter of 2016 with the objectives of: (1) assessing the 16-week efficacy of VTP-43742 in moderate to severe psoriasis patients; (2) assessing the safety of the Vitae Pharmaceuticals, Inc. Tel: (215) 461-2000 502 West Office Center Drive Fax: (215) 461-2006 Fort Washington, PA 19034 www.vitaepharma.com. Product candidate in a larger population and over a longer treatment period; and (3) positioning VTP-43742 to begin pivotal trials as soon as practicable after the completion of the Phase 2 clinical trial, if successful. Vitae expects to report top-line data from this trial in the second half of 2017. VTP-45489 in Autoimmune Disorders Vitae is advancing VTP-45489, its second RORγt inhibitor, into the clinic. Vitae expects to initiate a Phase 1 single ascending dose clinical trial in normal healthy volunteers during the third quarter of 2016. New Contour ® Program Animal proof-of-principle achieved in a new target program. Initial lead candidate selected to advance into preclinical development. Corporate Update: Appointed Carole Sable, M.D., as Chief Medical Officer. Dr. Sable will oversee the clinical development of Vitaes pipeline, including VTP-43742 and VTP-38543. Dr. Sable brings to Vitae more than 20 years of diverse clinical development and executive management experience, having been involved in all phases of clinical research. Appointed Daniel M. Junius to Vitaes Board of Directors. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc. and brings both executive and prior board experience to Vitaes Board of Directors. Financial Results: Operating Expense. Total operating expenses for the second quarter of 2016 were $10.5 million, compared with $10.0 million for the second quarter of 2015. Research and development expenses were $7. Download adobe premiere pro cs5 full crack 64 bit. 9 million for the second quarter of 2016, compared with $7.8 million for the second quarter of 2015. The slight increase was largely attributable to expenses related to preclinical programs, the atopic dermatitis program, discovery efforts, stock-based compensation and compensation expense, partially offset by reduced manufacturing expenses resulting from the timing of development activities for the RORγt program. General and administrative expenses were $2.7 million for the second quarter of 2016, compared with $2.3 million for the second quarter of 2015. The increase was primarily due to an increase in legal fees, patent related expenses, stock-based compensation expense and compensation expenses. Vitae reported a net loss of $10.4 million, or $0.36 per diluted share, for the second quarter of 2016, compared with a net loss of $9.8 million, or $0.45 per diluted share, for the second quarter of 2015. The increase in net loss was primarily due to the increase in general and administrative expenses. Cash Position. As of June 30, 2016, Vitae had $77.4 million in cash, cash equivalents and marketable securities, compared with $59.4 million as of December 31, 2015.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |